medigraphic.com
ISSN 1561-3062 (Electronic)

2021, Number 3

<< Back Next >>

Revista Cubana de Obstetricia y Ginecología 2021; 47 (3)

Prevalence and characterization of preeclampsia

Fajardo ToYL, Millán VMM, Ferrer FAM, Marzo PET

Language: Spanish
References: 25
Page: 1-13
PDF size: 444.47 Kb.


ABSTRACT

Introduction: Preeclampsia is an exclusive entity of the human species that appears during pregnancy, childbirth or the puerperium. Each year, ten million women suffer from it, and it is a leading cause of maternal morbidity directly linked to hemorrhage, caesarean section, low birth weight and perinatal and maternal mortality.
Objective: To determine the incidence of preeclampsia and characterize this disease from the epidemiological, clinical and humoral point of view, to create the basis for future analytical studies.
Methods: A cross-sectional observational study was carried out from April 2017 to March 2020 that included 195 patients with preeclampsia, treated at Carlos Manuel de Céspedes Provincial General Hospital in Bayamo, Granma.
Results: The prevalence of preeclampsia was 3.56%. The mean age was 26.7 years. Mean platelet count values were 220.4 per 109/L, glutamic-oxalacetic transaminase 29.2 IU, and creatinine 64.1 mmol/L. The high schooling level prevailed in the patients (74.7%). Late preeclampsia represented 80.2%. Pathological Doppler ultrasound of uterine arteries at 24 weeks of gestation was in 15.4% of the series.
Conclusions: The prevalence of preeclampsia in our study is lower than that reported in the literature reviewed. The results of the characterization can be used in analytical studies that will support the preventive actions of the disease.


REFERENCES

  1. Levine LD, Nkonde-Price C, Limaye M, Srinivas SK. Factors associate with Postpartum follow-up and persistent Hypertension among women with severe preeclampsia. J Perinatol. 2016;36(12):1079-82.

  2. American College of Obstetricians and Gynecologists. Hypertension in pregnancy. Report of the ACOG Task Force on Hypertension in Pregnancy. Obstetrics and Gynecology. 2013;122(5):1122-31.

  3. Reinebrant H, Leisher SH, Coory M, Henry S, Wojcieszek AM, Gardener G. Making stillbirths visible: a systematic review of globally reported causes of stillbirth. BJOG. 2018;125(2):212-24.

  4. Ray JG, Wanigaratne S, Park AL, Bartsch E, Dzakpasu S, Urquia ML. Preterm preeclampsia in relation to country of birth. J Perinatol. 2016;36(9):718-22.

  5. Turpin CA, Sakyi SA, Owiredu WK. Association between adverse pregnancy outcome and imbalance in angiogenic regulators and oxidative stress biomarkers in gestational hypertension and preeclampsia. BMC Pregnancy. Childbirth. 2015;15(1):189.

  6. Fajardo Tornés Y, Nápoles Méndez D, Álvarez Aliaga A, Millares Ross A, Ocaña Cabrales O. Prevalencia de la hipertensión crónica posparto en pacientes con antecedentes de preeclampsia. Hospital Carlos Manuel de Céspedes y del Castillo. Bayamo. Granma. Rev Cubana Obstet Ginecol. 2020;46(2).

  7. Reporte estadístico anual del hospital provincial general Carlos Manuel de Céspedes y del Castillo, Granma, Cuba: Dirección Provincial de Salud; 2018.

  8. Colectivo de autores. Capítulo 7. Guías de actuación en las afecciones obstétricas frecuentes. La Habana: Editorial de Ciencias Médicas; 2017. p. 50-74.

  9. Jim B, Karumanchi SA. Preeclampsia: pathogenesis, prevention, and long term complications. Semin Nephrol. 2017;37:386-97.

  10. Cines DB, Devine LD. Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program. 2017;1:144-51.

  11. Ávalos E, Cuesta C, Carroli G, Qureshi Z, Widmer M, Vogel JP, et al. Preeclampsia, eclampsia and adverse maternal and perinatal outcomes: a secondary analysis of the World Health Organization Multicountry Survey on Maternal and Newborn Health. BJOG. 2014;121(Suppl. 1):14-24.

  12. Cines DB, Devine LD. Thrombocytopenia in pregnancy. Hematology Am Soc Hematol Educ Program. 2017;1:144-51.

  13. Guerra Verdecia C, Fajardo Tornés Y. HELLP síndrome. Presentación de un caso y resumen de la entidad. Revista Cubana Obstet Ginecol. Abril. 2002;28(1):49-53.

  14. Subki AH, Algethami MR, Baabdullah WM. Prevalence, Risk factors, and fetal and maternal outcomes of hypertensive disorders of pregnancy: a retrospective study in western Saudi Arabia. Oman Med J. 2018;33(5):409-15. DOI: http://dx.doi.org/10.5001/omj.2018.75

  15. Agrawal S, Maitra N. Prediction of adverse maternal outcomes in preeclampsia using a risk prediction model. J Obstet Gynaecol India. 2016;66:104-11.

  16. Piccoli G, Zakharova E, Attini R, Ibarra Hernandez M, Covella B, Alrukhaimi M, et al. Acute kidney injury in pregnancy: the need for higher awareness. A pragmatic review focused on what could be improved in the prevention and care of pregnancy-related AKI, in the year dedicated to women and kidney diseases. J Clin Med. 2018;7(10):318.

  17. Pérez Ferreiro Y, Creagh Bandera I. Caracterización clínico epidemiológica de pacientes con enfermedad hipertensiva gravídica en el subdistrito Venilale de Timor Oriental. MEDISAN. 2017 [acceso 12/01/2019];21(2):aprox. 16 p. Disponible en: http://scielo.sld.cu/pdf/san/v21n2/san06212.pdf

  18. Akolekar R, Syngelaki A, Sarquis R, Zvanca M, Nicolaides K. Prediction of early, intermediate and late preeclampsia from maternal factors, biophysical and biochemical markers at 11 - 13 weeks. Prenat Diagn. 2011;31:66-74.

  19. Grand Maison S, Pilote L, Okano M, Landry T, Dayan N. Markers of vascular dysfunction after hypertensive disorders of pregnancy: a systematic review and meta-analysis. Hypertension. 2016;68(6):1447-58.

  20. Vigil-De Gracia P, Rojas-Suarez J, Ramos E, Reyes O, Collantes J, Quintero A, et al. Incidence of eclampsia with HELLP syndrome and associated mortality in Latin America. Int J Obstet Gynecol. 2015;129(3):219-22.

  21. Halland F, Morken NH, De Roo LA, Klungsoyr K, Wilcox AJ, Skjaerven R. Association of women's reproductive history with long-term mortality and effect of socioeconomic factors. Obstet Gynecol. 2015;126(6):1181-7.

  22. Fox R, Kitt J, Leeson P, Aye CYL, Lewandowski AJ. Preeclampsia: risk factors, diagnosis, management, and the cardiovascular impact on the off spring. J Clin Med. 2019;1625(8):1-22.

  23. Williams B, Mancia G, Spiering W, Rosei EA, Azizi M, Burnier M, et al. 2018 ESC/ESH Guidelines for the management of arterial hypertension. Kardiol Pol. 2019 [acceso 23/03/2020];77(2):71-159. Disponible en: https://pubmed.ncbi.nlm.nih.gov/30816983/

  24. Easterling T, Mundle S, Bracken H, Parvekar S, Mool S, Magee LA, et al. Oral antihypertensive regiments (nifedipine retard, labetalol, and methyldopa) for management of severe hypertension in pregnancy: an open-label, randomized controlled trial. Lancet. 2019;394:1011-21. DOI: https://dx.doi.org/10.1016/S0140-6736(19)31282-6

  25. Protocolo actualizado para el manejo de los trastornos hipertensivos. La Habana, Cuba: Ministerio de Salud Pública de Cuba; 2017.




2020     |     www.medigraphic.com